We don’t have all the answers, but we’ll work with anyone who does

The cost of developing innovative medicines can be exorbitantly high, which all too often results in life-saving therapies being out of reach for the people that need them most.

This is a complex challenge that we don’t have to tackle alone, which is why we are forging meaningful and collaborative partnerships with any company from any country that will allow us to positively impact more people worldwide.

Our current partnerships

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) and Elevar Therapeutics (Elevar) have a global clinical collaboration to evaluate the safety and efficacy of Elevar’s rivoceranib (also known as apatinib) in combination with Hengrui Pharma’s camrelizumab in patients with advanced hepatocellular carcinoma (HCC). Luzsana Biotechnology™, in partnership with Elevar, is evaluating commercialization opportunities in markets outside of China.

HCC typically has a poor prognosis and a lack of treatment options. This collaboration has the potential to help more patients with advanced HCC, a condition with an urgent medical need.

Hear from our leadership team about how they are
daring to take a different approach to healthcare.